Navigation Links
Misonix Announces Change in Distribution of BoneScalpel™ Bone Cutting System in the U.S.

FARMINGDALE, N.Y., March 16, 2011 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a medical device company that designs, manufactures, and markets innovative, therapeutic, ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has announced a definitive agreement for non-exclusive distribution, with the exception of certain selected accounts, of the BoneScalpel Ultrasonic Bone Cutting System in the United States with Aesculap, Inc., which replaces a prior exclusive distribution agreement between the parties.  The agreement is limited to clinical applications relative to the spine and cranium.

In response, Misonix will begin the marketing, sales, distribution and service of the BoneScalpel in the U.S., effective immediately, utilizing its 75 person surgical sales organization, which markets direct to hospitals and free-standing surgery centers.  In addition to spine and cranial applications, the Misonix sales organization will market the product for a broad range of maxiofacial and other small bone clinical applications.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument while minimizing the peril associated with rotary sharps.

"Misonix is excited about adding BoneScalpel to our focused, domestic sales organization.  With this Agreement, Misonix will now be selling the BoneScalpel worldwide," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.  "Over time, we anticipate significant margin improvement and sales growth by allowing our proprietary sales organization the opportunity to sell another one of our key products under the Misonix label."

About Misonix:Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.Investor Relations Contact:Kevin McGrath/Cameron Associates,

SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix to Present at the ROTH Capital Growth Stock Conference on March 15, 2011
2. Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results
3. Misonix Announces Completion of Product Registrations in Key Latin American Markets
4. Misonix Schedules Second Quarter 2011 Financial Results Conference Call; February 9, 2011 at 4:30 p.m. Eastern
5. Misonix to Present at Sidoti & Company 2011 Micro Cap Conference
6. Misonix Announces Achievement of Contract Vendor Status With Select Medical Corporation
7. Misonix Previews New OsteoSculpt® Ultrasonic Bone Scalpel
8. Misonix Reports First Quarter Fiscal 2011 Financial Results
9. Misonix Announces New Distribution Agreement for South Africa
10. Misonix Schedules First Quarter 2011 Financial Results Conference Call; November 15, 2010 at 4:30 P.M. Eastern
11. Misonix Announces Change in Distribution of SonaStar® Surgical Aspiration System in the U.S.
Post Your Comments:
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... , 1 de diciembre de 2015 ... tecnología para cuchillas de precisión, develó hoy ... de identidad de marca. El nuevo logo ... diseño y la ingeniería de productos con ... diferencia". ...
(Date:12/1/2015)... -- Six months of adjunctive metformin therapy does not improve glycemic ... new research from T1D Exchange and funded by ... effect on measures of obesity, including weight and BMI. The ... of the American Medical Association , are from the largest ... overweight and obese adolescents with type 1 diabetes. ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... , ... Florida Hospital Tampa is the first health care provider in the region ... , vBloc® Therapy is a vagal blocking therapy, delivered via the Maestro® System, for the ... (BMI) of at least 40 to 45 kg, or a BMI of at least 35 ...
(Date:12/1/2015)... ... , ... Dr. Paul Vitenas, one of the top cosmetic surgeons in ... as the Best Single Physician Practice in the nation. Dr. Vitenas and his practice ... by the industry publication. , Dr. Vitenas said he was very honored to ...
(Date:12/1/2015)... ... 01, 2015 , ... CloudLIMS today announced that it is ... under the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's ...
(Date:12/1/2015)... ... December 01, 2015 , ... For ... mark the film for accurate interpretation by the radiologist. The marking utensils are ... from Sacramento, Calif., has found a way to alleviate this problem. , He ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announced it has been awarded a fixed price per sprint agile development contract ... valued at $34 million over five years, provides software engineering, infrastructure, as well ...
Breaking Medicine News(10 mins):